- Facing pharmacy trends for the remainder of the year
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- Walgreens, Rite Aid join outcry over Boston Rolling Stone cover
- Study questions drug-discount programs
NEW YORK — French drug maker Sanofi announced a deal with the Global Alliance for TB Drug Development to develop drugs for tuberculosis.
The drug maker and the TB Alliance said the deal will include discovery and development of new drug compounds for the disease, which caused almost 1.5 million deaths globally and affected nearly 9 million in 2010, according to the World Health Organization.
Under the agreement, the two will work on several new compounds in Sanofi's library that have shown effectiveness against the bacterium that causes TB, known as Mycobacterium tuberculosis. This will include in-depth research of lead compounds and the chemical optimization of compounds that have been identified as hits through high-throughput screening.